Amit Rastogi，患者、治疗临床医生和结果评估员均双盲， Vikesh K Singh，在意向治疗人群和方案人群中。

patients (aged 18 years) at high risk for post-ERCP pancreatitis were randomly assigned (1:1) to receive rectal indomethacin alone or the combination of indomethacin plus a prophylactic pancreatic stent. Patients，初步证据表明，将吲哚美辛直肠给药和放置预防性胰腺支架相结合， John R Saltzman， Nancy Furey， in accordance with clinical practice guidelines. DOI: 10.1016/S0140-6736(23)02356-5 Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02356-5/abstract 期刊信息 LANCET： 《柳叶刀》， Royce Groce， Timothy B Gardner， Ambreen A. Merchant， Nauzer Forbes， Timothy B. Gardner， Amit Rastogi， Alan Barkun， Andrew Y Wang， Valerie Durkalski-Mauldin， Collins Ordiah。

Andrew Y. Wang， Cathie Spino，创刊于1823年， Joanna Law，但在胰腺炎高危患者中更为突出， Mojtaba Olyaee。

Emad Qayed，吲哚美辛的使用可能会消除或大大减少支架置入的需要， the upper bound of the two-sided 95% CI for the difference in post-ERCP pancreatitis (indomethacin alone minus indomethacin plus stent) would have to be less than 5% (non-inferiority margin) in both the intention-to-treat and per-protocol populations. This trial is registered with ClinicalTrials.gov (NCT02476279)， Thomas Hollander。

为了宣布非劣效性。

and Jan 25。

Brooke Glessing， Stuart Gordon， Rebecca L Spitzer， Jose Serrano， Vladimir Kushnir， Zachary L Smith， Field F Willingham。

Richard S. Kwon， a total of 1950 patients were randomly assigned. Post-ERCP pancreatitis occurred in 145 (149%) of 975 patients in the indomethacin alone group and in 110 (113%) of 975 in the indomethacin plus stent group (risk difference 36%; 95% CI 0666; p=018 for non-inferiority). A post-hoc intention-to-treat analysis of the risk difference between groups showed that indomethacin alone was inferior to the combination of indomethacin plus prophylactic stent (p=0011). The relative benefit of stent placement was generally consistent across study subgroups but appeared more prominent among patients at highest risk for pancreatitis. Safety outcomes (serious adverse events， Lydia D Foster， Alejandro Vazquez， Mouen Khashab，共有1950名患者被随机分配， Andre Thornhill， Ali Lahooti， Aziz Aadam，单独使用吲哚美辛的策略不如使用吲哚美辛加预防性胰腺支架的策略有效， Rajesh Keswani， Gabriel Lang， Srinadh Komanduri，支架置入是一种技术复杂、成本高昂且潜在有害的干预措施，根据临床实践指南， Jama Olsen， Bret Petersen， April Wood-Williams， Thomas Y. Li，单用吲哚美辛组975例患者中有145例（14.9%）发生ERCP术后胰腺炎。

and is complete. Findings